X Wu, Y Zhang, T Hu, X He, Y Zou, Q Deng… - Molecular …, 2021 - europepmc.org
Screening for early‐stage disease is vital for reducing colorectal cancer (CRC)‐related mortality. Methylation of circulating tumor DNA has been previously used for various types of …
X Wu, Y Zhang, T Hu, X He, Y Zou, Q Deng… - Molecular …, 2021 - search.proquest.com
Screening for early-stage disease is vital for reducing colorectal cancer (CRC)-related mortality. Methylation of circulating tumor DNA has been previously used for various types of …
X Wu, Y Zhang, T Hu, X He, Y Zou… - Molecular …, 2021 - pubmed.ncbi.nlm.nih.gov
Screening for early-stage disease is vital for reducing colorectal cancer (CRC)-related mortality. Methylation of circulating tumor DNA has been previously used for various types of …
J Ke, L Lian, X He, D Zhao, X Cai, Z Chen, X Wu… - scholar.archive.org
Colorectal cancer (CRC) is the third most common malignant neoplasm globally [1]. Despite improvements in treatment, the prognosis of CRC patients with advanced TNM stage …
X Wu, Y Zhang, T Hu, X He, Y Zou, Q Deng… - Molecular …, 2021 - ncbi.nlm.nih.gov
Screening for early‐stage disease is vital for reducing colorectal cancer (CRC)‐related mortality. Methylation of circulating tumor DNA has been previously used for various types of …